Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791564 | 0.85 | ALDH1A1 (0.47) | RAB9AALDH1A1HTTNPC1CA12 | |
| SCHEMBL23358048 | 0.80 | RECQL (0.51) | RAB9AALDH1A1HTTNPC1CA12 | |
| SCHEMBL21564566 | 0.77 | HTR2C (0.45) | TACR1HSP90AA1 | |
| SCHEMBL20338982 | 0.77 | KMT2A (0.65) | RAB9AALDH1A1HTTNPC1KMT2A | |
| SCHEMBL6121488 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL18317001 | 0.75 | TACR1 (0.49) | RAB9AALDH1A1HTTNPC1CA12 | |
| SCHEMBL21528103 | 0.74 | RAB9A (0.42) | RAB9AALDH1A1HTTNPC1CA12 | |
| SCHEMBL20344316 | 0.74 | SMN1; SMN2 (0.54) | ALDH1A1KMT2AAOC3SMN1; SMN2 | |
| SCHEMBL3326164 | 0.74 | ALDH1A1 (0.51) | RAB9AALDH1A1HTTNPC1KMT2A | |
| SCHEMBL19949104 | 0.73 | KMT2A (0.45) | RAB9AALDH1A1NPC1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | RAB9A 352/4885ALDH1A1 3733/4885HTT 2816/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | RAB9A 352/4885ALDH1A1 3733/4885HTT 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.